RecruitingNot ApplicableNCT06813573
Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Enrollment
50 participants
Start Date
Sep 30, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The goal of this study is to prospectively follow the level of circulating nucleosomes in patients treated for a non-Hodgkin lymphoma and determine whether it correlates with the clinical response.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Histologically proven diagnosis of diffuse large B cell lymphoma or follicular lymphoma, according to the WHO 2016 classification, requiring a first line of treatment with a RCHOP 21 regimen
- Agreement to participate after receiving oral and written information on the study
Exclusion Criteria2
- History of previous treatment for lymphoma (excluding localized low dose radiotherapy in the case of follicular lymphoma)
- Treatment with a chemotherapy regimen different from RCHOP21
Interventions
BIOLOGICALblood sampling
A maximum of 4 tubes of 10ml will be collected: at baseline (before cycle 1), before each cycle (from 2 to 6 included), at the end of the treatment, and in case of relapse during follow-up period
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06813573
Related Trials
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
NCT05006716120 locations
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
NCT0459464227 locations
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
NCT060263191 location
Odronextamab in Low Tumor Volume Advanced FL
NCT071286411 location
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
NCT065103613 locations